NCT00496587View on ClinicalTrials.gov

Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Renal Cell CarcinomaKidney Cancer
Interventions
DRUG

Capecitabine

800 mg/m\^2 By Mouth Twice Daily On Days 1-21.

DRUG

Gemcitabine

900 mg/m\^2 By Vein Over 30 Minutes on Days 1 and 15.

DRUG

Bevacizumab

10 mg/kg By Vein On Days 1 and 15.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00496587 - Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter